Connor Clark & Lunn Investment Management Ltd. Has $3.93 Million Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 819,382 shares of the biopharmaceutical company’s stock after purchasing an additional 38,449 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 1.41% of Vanda Pharmaceuticals worth $3,925,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of VNDA. Massachusetts Financial Services Co. MA acquired a new position in Vanda Pharmaceuticals in the third quarter valued at about $864,000. Geode Capital Management LLC grew its position in Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock valued at $6,689,000 after acquiring an additional 94,870 shares during the last quarter. Barclays PLC grew its position in Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 86,677 shares during the last quarter. BNP Paribas Financial Markets grew its position in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 57,393 shares during the last quarter. Finally, FMR LLC grew its position in Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 30,802 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 1.2 %

NASDAQ:VNDA opened at $4.98 on Monday. The stock has a market cap of $290.41 million, a P/E ratio of -15.56 and a beta of 0.69. The stock’s 50-day moving average is $4.61 and its 200-day moving average is $4.76. Vanda Pharmaceuticals Inc. has a 1-year low of $3.71 and a 1-year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million for the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright lifted their target price on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th.

Insider Transactions at Vanda Pharmaceuticals

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average cost of $4.76 per share, with a total value of $47,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have bought 32,000 shares of company stock worth $151,180. Insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.